Canakinumab is a human anti-IL-1β monoclonal antibody, and clinically used for FCAS, MWS, CAPS, familial Mediterranean fever (FMF), mevalonate kinase deficiency (MKD), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), and AOSD (15). The gene discussed is IL1B; the disease is hyperinsulinemic hypoglycemia, familial, 4.